JP6800854B2 - 多能性幹細胞の懸濁培養 - Google Patents

多能性幹細胞の懸濁培養 Download PDF

Info

Publication number
JP6800854B2
JP6800854B2 JP2017532641A JP2017532641A JP6800854B2 JP 6800854 B2 JP6800854 B2 JP 6800854B2 JP 2017532641 A JP2017532641 A JP 2017532641A JP 2017532641 A JP2017532641 A JP 2017532641A JP 6800854 B2 JP6800854 B2 JP 6800854B2
Authority
JP
Japan
Prior art keywords
cells
stage
medium
expression
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017532641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537649A (ja
JP2017537649A5 (enExample
Inventor
フライヤーズ，ベンジャミン
ラニアウスカス，ダイナ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド, ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2017537649A publication Critical patent/JP2017537649A/ja
Publication of JP2017537649A5 publication Critical patent/JP2017537649A5/ja
Application granted granted Critical
Publication of JP6800854B2 publication Critical patent/JP6800854B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/19—Growth and differentiation factors [GDF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017532641A 2014-12-19 2015-12-09 多能性幹細胞の懸濁培養 Active JP6800854B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094509P 2014-12-19 2014-12-19
US62/094,509 2014-12-19
PCT/US2015/064713 WO2016100035A1 (en) 2014-12-19 2015-12-09 Suspension culturing of pluripotent stem cells

Publications (3)

Publication Number Publication Date
JP2017537649A JP2017537649A (ja) 2017-12-21
JP2017537649A5 JP2017537649A5 (enExample) 2019-02-07
JP6800854B2 true JP6800854B2 (ja) 2020-12-16

Family

ID=56127372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017532641A Active JP6800854B2 (ja) 2014-12-19 2015-12-09 多能性幹細胞の懸濁培養

Country Status (16)

Country Link
US (1) US20160215268A1 (enExample)
EP (1) EP3234109A4 (enExample)
JP (1) JP6800854B2 (enExample)
KR (3) KR102281752B1 (enExample)
CN (1) CN107250349A (enExample)
AR (1) AR103080A1 (enExample)
AU (1) AU2015363008B2 (enExample)
BR (1) BR112017012974A2 (enExample)
CA (1) CA2970935A1 (enExample)
MX (1) MX2017008176A (enExample)
PH (1) PH12017501153A1 (enExample)
RU (1) RU2017125728A (enExample)
SG (1) SG11201704961VA (enExample)
TW (1) TW201636421A (enExample)
WO (1) WO2016100035A1 (enExample)
ZA (1) ZA201704868B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3012603A1 (en) 2016-01-26 2017-08-03 Centre For Commercialization Of Regenerative Medicine Method for dissociating cell aggregates
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
EP4488363A3 (en) * 2017-07-21 2025-03-26 Vertex Pharmaceuticals Incorporated Re-aggregation of stem cell-derived pancreatic beta cells
AU2018330499B2 (en) * 2017-09-11 2025-01-30 Novo Nordisk A/S Enrichment of NKX6.1 and C-peptide co-expressing cells derived in vitro from stem cells
AU2018370029B2 (en) 2017-11-15 2024-11-07 Vertex Pharmaceuticals Incorporated Islet cell manufacturing compositions and methods of use
AU2019320072A1 (en) 2018-08-10 2021-02-25 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
SG11202102748WA (en) * 2018-09-19 2021-04-29 Takeda Pharmaceuticals Co Insulin-producing cells
EP3953451A1 (en) * 2019-04-08 2022-02-16 Novo Nordisk A/S Generation of pancreatic endoderm from stem cell derived definitive endoderm
AU2020283056B2 (en) 2019-05-31 2023-06-08 Viacyte, Inc. A biocompatible membrane composite
CA3139585C (en) 2019-05-31 2024-01-23 W. L. Gore & Associates, Inc. A biocompatible membrane composite
CA3139292C (en) 2019-05-31 2025-06-10 Viacyte, Inc. CELL ENCAPSULATION DEVICES WITH REGULATED OXYGEN DIFFUSION DISTANCES
US20220234006A1 (en) 2019-05-31 2022-07-28 W. L. Gore & Associates, Inc. A biocompatible membrane composite
CA3150233A1 (en) 2019-09-05 2021-03-11 Alireza Rezania Universal donor cells
CN114375300A (zh) 2019-09-05 2022-04-19 克里斯珀医疗股份公司 通用供体细胞
AU2021414405A1 (en) 2020-12-31 2023-08-10 Crispr Therapeutics Ag Universal donor cells
CN119432595A (zh) * 2023-08-07 2025-02-14 浙江霍德生物工程有限公司 利用生物反应器进行诱导多能干细胞的悬浮培养
WO2025117331A1 (en) * 2023-12-01 2025-06-05 Eli Lilly And Company Methods of making stem cell-derived islet-like cells, as well as populations and compositions including the same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
CN1602351B (zh) 2001-12-07 2011-03-30 杰龙公司 源自人胚胎干细胞的胰岛细胞
PL1641916T3 (pl) 2003-06-27 2016-08-31 Depuy Synthes Products Inc Regeneracja i naprawa tkanki nerwowej z wykorzystaniem komórek poporodowych
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
SG149061A1 (en) 2003-12-23 2009-01-29 Cythera Inc Definitive endoderm
CA2560581C (en) 2004-03-23 2013-06-11 Toshihiro Akaike Pluripotent stem cell growing method
GB2437689B (en) 2005-01-28 2009-10-28 Novathera Ltd Culture and screening methods
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
EP3354723B1 (en) 2005-08-29 2023-12-13 Technion Research & Development Foundation Ltd. Media for culturing stem cells
ES2743202T3 (es) * 2005-10-27 2020-02-18 Viacyte Inc Endodermo de intestino proximal dorsal y ventral que expresa PDX1
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
EP4112718A1 (en) * 2006-03-02 2023-01-04 ViaCyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
AU2007277364B2 (en) 2006-07-26 2010-08-12 Viacyte, Inc. Methods of producing pancreatic hormones
EP2733203B1 (en) 2006-08-02 2018-10-10 Technion Research & Development Foundation Ltd. Methods of expanding embryonic stem cells in a suspension culture
DK2173863T3 (en) 2007-06-29 2019-01-21 Fujifilm Cellular Dynamics Inc Automated method and apparatus for embryonic stem cell culture
EP2942392B1 (en) * 2008-06-30 2018-10-03 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
WO2010022395A2 (en) * 2008-08-22 2010-02-25 President And Fellows Of Harvard College Methods of reprogramming cells
PL2494035T3 (pl) 2009-10-29 2018-07-31 Janssen Biotech, Inc. Pluripotencjalne komórki macierzyste
CN103068970A (zh) * 2010-04-25 2013-04-24 西奈山医学院 来自多能细胞的前部前肠内胚层的形成
MX2014007744A (es) * 2011-12-22 2015-01-12 Janssen Biotech Inc Diferenciacion de celulas madre embrionicas humanas en celulas individuales positivas de insulina hormonal.
ES2942484T3 (es) * 2012-12-31 2023-06-01 Janssen Biotech Inc Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas usando reguladores de HB9
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells

Also Published As

Publication number Publication date
TW201636421A (zh) 2016-10-16
CN107250349A (zh) 2017-10-13
JP2017537649A (ja) 2017-12-21
AU2015363008A1 (en) 2017-06-29
KR102700499B1 (ko) 2024-08-28
BR112017012974A2 (pt) 2018-01-09
WO2016100035A1 (en) 2016-06-23
US20160215268A1 (en) 2016-07-28
KR102281752B1 (ko) 2021-07-23
CA2970935A1 (en) 2016-06-23
RU2017125728A (ru) 2019-01-22
PH12017501153A1 (en) 2017-11-27
AU2015363008B2 (en) 2021-12-09
EP3234109A1 (en) 2017-10-25
MX2017008176A (es) 2018-02-09
SG11201704961VA (en) 2017-07-28
RU2017125728A3 (enExample) 2019-06-03
AR103080A1 (es) 2017-04-12
KR20170087520A (ko) 2017-07-28
KR20230050478A (ko) 2023-04-14
ZA201704868B (en) 2019-02-27
KR20210094141A (ko) 2021-07-28
KR102519502B1 (ko) 2023-04-06
EP3234109A4 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
JP6800854B2 (ja) 多能性幹細胞の懸濁培養
JP6529440B2 (ja) 膵内分泌細胞への分化のためのヒト多能性細胞の懸濁及びクラスタリング
AU2014343007C1 (en) Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
US10370644B2 (en) Method for making human pluripotent suspension cultures and cells derived therefrom

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201125

R150 Certificate of patent or registration of utility model

Ref document number: 6800854

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250